Healthcare Industry News: Elan Corp
News Release - March 25, 2008
APP Pharmaceuticals Launches Cefepime Hydrochloride for InjectionSCHAUMBURG, Ill.--(HSMN NewsFeed)--APP Pharmaceuticals, Inc. (Nasdaq:APPX ), a leading manufacturer of multi-source and branded injectable pharmaceutical products, today announced that it has launched Cefepime Hydrochloride for Injection, the generic equivalent of Maxipime® marketed by Elan Corporation, plc. APP’s cefepime is AP-rated, bar-coded and latex-free. According to IMS data, sales of Cefepime Hydrochloride in the United States were approximately $173 million in 2007.
Cefepime Hydrochloride for Injection is indicated in the treatment of the following infections: Pneumonia, Empiric Therapy for Febrile Neutropenic Patients, Urinary Tract Infections (including pyelonephritis), Skin and Skin Structure Infections, and Intra-abdominal Infections.
“The launch of Cefepime further bolsters our leadership position as a provider of the broadest portfolio of generic anti-infective injectable products,” said Tom Silberg, President of APP. “APP is one of the only marketers of first, second, third and fourth generation cephalosporin in the U.S.”
About APP Pharmaceuticals
APP is a specialty drug company that develops, manufactures and markets injectable pharmaceutical products, focusing on oncology, anti-infective, anesthetic/analgesic and critical care markets. The company is one of the largest producers of injectables, with more than 100 products in more than 400 dosage formulations. APP, headquartered in Schaumburg, Illinois, has offices in Canada and manufacturing operations in Illinois, New York and Puerto Rico and is traded on the Nasdaq Global Market under the symbol APPX. For more information about APP and the products it provides, please visit www.APPpharma.com.
The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of cefepime hydrochloride for injection. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in APP Pharmaceuticals Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission.
The information contained in this news release is as of the date of this release. APP assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.
Source: APP Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.